Oxis 6 Turbohaler (AstraZeneca UK Ltd) 60 dose

Type Dry powder inhaler (DPI)
Medicine Formoterol 6micrograms/dose
Activation mechanism Breath actuated
Dose counter Has dose counter
Price £49.60 / 30 days
(based on 4 puffs / day)
Licences
  • Adult Asthma Licence
  • Adolescent Asthma Licence age range not available
  • Paediatric Asthma Licence 6 years and older
  • COPD Licence

Training material

Pathways

The use of each medicine included in Right Breathe has been considered in relation to international, national, and regional prescribing pathways. The pathway points at which this medicine is considered a viable prescribing option are included below. If you wish to view the entire pathway, click on its heading, from where you can also access all the prescribing options for each pathway and each pathway point.

Prescribing

Detailed prescribing information is provided below. This content has not been generated by the RightBreathe team, but has been integrated from a 3rd party solution: Multilex (provided by FirstDataBank). Use of this prescribing content is subject to the FirstDataBank disclaimer, which is set out in the "About" section of RightBreathe.

As RightBreathe is a bespoke decision support tool, it covers each and every individual known inhaler option on the UK market to a high level of specificity. Multilex, as a more general resource, does not offer the same level of specificity. There are therefore a small number of medicines for which there are discrepancies between RightBreathe and Multilex content, most notably in relation to licensed particulars and associated licensed doses.

Given the high level of specificity the RightBreathe team work to, details of the individual inhaler licence are most likely to be summarised accurately in the content provided at the top of this page, rather than in the Multilex content below. Where there is ambiguity, users may also wish to refer to individual summaries of product characteristics prior to prescribing.

Dosing

Prophylaxis of bronchial asthma where inhaled corticosteroid is indicated

Type Age Range Dose Licensed
Maintenance From 6 years 1 actuation - ONCE a DAY - inhalation
Maintenance From 6 years 1 actuation - TWICE a DAY - inhalation
Maintenance From 6 years 2 actuations - FOUR times a DAY - inhalation
Maintenance From 6 years 2 actuations - TWICE a DAY - inhalation
Maintenance From 18 years 4 actuations - ONCE a DAY - inhalation
Maintenance From 18 years 4 actuations - TWICE a DAY - inhalation

Prevention of exercise-induced bronchospasm

Type Age Range Dose Licensed
Maintenance From 6 years to 18 years 1 actuation - when required - 10 to 15 minutes before exertion - inhalation
Maintenance From 6 years 2 actuations - when required - 10 to 15 minutes before exertion - inhalation

Symptom relief of broncho-obstruction in asthma when steroids insufficient

Type Age Range Dose Licensed
Maintenance From 6 years 1 actuation - when required - inhalation
Maintenance From 6 years 2 actuations - when required - inhalation

Chronic obstructive pulmonary disease

Type Age Range Dose Licensed
Maintenance From 18 years 2 actuations - ONCE a DAY - inhalation
Maintenance From 18 years 2 actuations - TWICE a DAY - inhalation

Symptom relief of bronchospasm in chronic obstructive pulmonary disease

Type Age Range Dose Licensed
Maintenance From 18 years 1 actuation - when required - inhalation
Maintenance From 18 years 2 actuations - when required - inhalation
Maintenance From 18 years 4 actuations - when required - inhalation

Safety Advice Warnings

Adverse effects (report/action)

  • CSM (CHM) requests reporting of adverse reactions to cfc-free inhalers

Advice concerning formulation

  • Not all available brands are licensed for all indications
  • Not all available brands are licensed for use in children under 12 years

Advice on drug withdrawal

  • Do not withdraw this drug suddenly

Advice on possible excipients

  • Some formulations contain lactose

Discontinue due to test or exam

  • Discontinue at least 12 hours before the start of anaesthesia
  • Discontinue if paradoxical bronchospasm occurs

Dose changes (other conditions)

  • Adjustment of hypoglycaemic therapy may be necessary in diabetes mellitus
  • Maintain treatment at the lowest effective dose

Patient Counselling

  • Advise patient dizziness may affect ability to drive or operate machinery
  • Advise patient not to exceed stated dose
  • Advise patient that CFC-free inhalers may have different taste or sensation
  • Advise patient to continue taking corticosteroid therapy
  • Patient should seek medical advice if usual relief is diminished

Pre-treatment points to consider

  • Do not substitute for steroid therapy
  • Not to be used as the sole or main treatment for severe or unstable asthma
  • Therapy should not be initiated during exacerbation of asthma

Recommended monitoring

  • Check patient is using correct inhaler technique
  • If frequent need for prophylaxis of exercise induced asthma,review therapy
  • Monitor serum K+ in patients on high dose steroids/xanthines/diuretics
  • Monitor serum potassium regularly in patients with severe asthma

Drug Interactions

With Risk Severity
(LEVACETYLMETHADOL) Hypokalaemia with high dose beta-agonist increases risk of arrhythmias Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
ATOMOXETINE May increase risk of cardiac effects Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
DOMPERIDONE Predisposing factors may increase risk of arrhythmias Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
METHACHOLINE Methacholine effect reduced; review dosing, see product literature Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
SOTALOL Effect antagonised/ predisposing factors increase risk of arrhythmias Significant Risk: Usually avoid combination. Use combination only under special circumstances, taking any necessary action to reduce risk.
(ASTEMIZOLE) Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
(HALOFANTRINE) Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
(RETIGABINE) Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
(SODIUM STIBOGLUCONATE) Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
AJMALINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
AMIFAMPRIDINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
AMIODARONE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ANAGRELIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ARSENIC TRIOXIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ARTEMETHER AND LUMEFANTRINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
AVAPRITINIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
AZITHROMYCIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CHLOROQUINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CILOSTAZOL Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CIPROFLOXACIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CITALOPRAM / ESCITALOPRAM Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
CLARITHROMYCIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
COCAINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
DELAMANID Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
DISOPYRAMIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
DONEPEZIL Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
DRONEDARONE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
DROPERIDOL Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ENTRECTINIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ERYTHROMYCIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ETELCALCETIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
FLECAINIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
FLUCONAZOLE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
GLASDEGIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
HALOPERIDOL Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
HYDROXYCHLOROQUINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
HYDROXYZINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
IBUTILIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
INOTUZUMAB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
IVOSIDENIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
LEVOFLOXACIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
MELPERONE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
METHADONE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
MOBOCERTINIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
MOXIFLOXACIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ONDANSETRON Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
OSILODROSTAT Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
OSIMERTINIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
OXALIPLATIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PAPAVERINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PENTAMIDINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PHENOTHIAZINES (QT 1) Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PIMOZIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PIPERAQUINE AND ARTENIMOL Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PRALSETINIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
PROPOFOL Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
QUINIDINE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
SELPERCATINIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
SERTINDOLE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
SEVOFLURANE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
SULPIRIDE Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
TERLIPRESSIN Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
VANDETANIB Predisposing factors may increase risk of arrhythmias Moderate Risk: Minimise risk. Take action necessary to reduce risk. Counsel patient.
ACE INHIBITORS WITH THIAZIDE DIURETICS Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
ACETAZOLAMIDE Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
ANGIOTENSIN II INHIBITORS AND THIAZIDE DIURETICS Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
BETA BLOCKER EYE DROPS May antagonise effect of each other Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
BETA BLOCKERS May antagonise effect of each other Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
BETA BLOCKERS AND THIAZIDE DIURETICS May antagonise effect of each other Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
LOOP DIURETICS Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
THEOPHYLLINE Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.
THIAZIDE DIURETICS Increased risk of hypokalaemia with high doses of beta agonist Low Risk: No action needed. Risk of adverse outcomes appears small and depends upon the condition of the patient. Counsel patient.

Precautions

  • Arterial aneurysm
  • Breastfeeding
  • Cardiac arrhythmias
  • Cardiac disorder
  • Children 6 to 12 years
  • Diabetes mellitus
  • Galactosaemia
  • Glucose-galactose malabsorption syndrome
  • Hepatic cirrhosis
  • Hyperthyroidism
  • Hypertrophic obstructive cardiomyopathy
  • Hypokalaemia
  • Idiopathic subvalvular aortic stenosis
  • Ischaemic heart disease
  • Lactose intolerance
  • Long QT syndrome
  • Occlusive peripheral vascular disorder
  • Phaeochromocytoma
  • Pregnancy
  • Severe decompensated cardiac failure
  • Severe hypertension
  • Third degree atrioventricular block
  • Thyrotoxicosis

Contraindications

  • Children under 6 years

Side Effects

  • Agitation
  • Angina pectoris
  • Angioedema
  • Anxiety
  • Arrhythmias
  • Atrial fibrillation
  • Behavioural disturbances
  • Blood pressure changes
  • Bronchospasm
  • Bronchospasm (paradoxical)
  • CNS stimulation
  • Cough
  • Dizziness
  • Dry mouth
  • Dysgeusia
  • Dyspnoea
  • Exacerbation of pre-existing asthma
  • Exanthema
  • Hallucinations
  • Headache
  • Hyperglycaemia
  • Hyperhidrosis
  • Hypersensitivity reactions
  • Hypertension
  • Hypokalaemia
  • Hypotension
  • Insomnia
  • Muscular cramps
  • Myalgia
  • Nausea
  • Nephritis
  • Nervousness
  • Oropharyngeal irritation
  • Palpitations
  • Peripheral oedema
  • Prolongation of QT interval
  • Pruritus
  • Rash
  • Restlessness
  • Sleep disturbances
  • Supraventricular tachycardia
  • Tachycardia
  • Taste disturbances
  • Thrombocytopenia
  • Tremor
  • Urticaria
  • Ventricular extrasystoles